Study S001627

Hormonal Regulation of Systolic Blood Pressure in Response to the GLP-1 (Glucagon-Like Peptide-1) Receptor Agonist, Liraglutide.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01755572
Acronym: BOLT
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: TRIPLE
Status: COMPLETED
Enrollment: 22
Start: 2013-01
Primary completion: 2014-01
Lead sponsor: Mount Sinai Hospital, Canada
Conditions: Type 2 Diabetes; Systolic Hypertension
Interventions: DRUG:Liraglutide; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Change in plasma ANP level at 1 Day [Change from Baseline compared in plasma ANP following 1 dose of liraglutide (0.6 mg) compared to crossover treatment with placebo at the 2-hour timepoint]
Change in plasma ANP level at 21 Days [Change from Baseline in plasma ANP following 21 days of liraglutide (titrated to 1.8 mg) compared to crossover treatment with placebo at the 2-hour timepoint]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0022910	Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Lovshin JA, Diabetes care	2015	Randomized trial	PMID 25414155 DOI	cites ClinicalTrials.gov:NCT01755572; registry reference RESULT:25414155